drugset / Trial / NCT04351620

High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19

NCT04351620

Phase 1 Completed 12 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

This study aims to examine the tolerability of high dose hydroxychloroquine in patients with COVID-19 who are not yet hospitalized, but have risk factors for disease progression and complications.

Timeline

Start
2020-04-20
Primary completion
2020-06-10
Completion
2020-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 1200 mg

Indications